Analysis of more than 880 clinical trials shows that while statistical data monitoring and key risk indicator signals close on similar timelines, durability—not speed—is the defining differentiator in effective, risk-based quality management.
Melissa Thomas
Advertisement
Central Monitor Consultant, CluePoints
Articles by Melissa Thomas
To maximize the impact of signal detection, KRI frameworks should follow a few guiding principles.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
3
ACT Brief: Community Trial Access Technology, RBQM Infrastructure, and Digital Clone Use Cases
4
What It Would Take to Make Community Trials Accessible and Scalable
5